MRK Should I Buy

Goldman Sachs analyst Asad Haider raised the firm's price target on Merck to $133 from $120 and keeps a Buy rating on the shares. Merck shares rose 2.2% despite broadly anticipated 2026 guidance, as focus remains on a string of upcoming late-stage clinical readouts, including Winrevair's CADENCE Phase 2 data, tulisokibart immunology trials, islatravir-based HIV regimen Phase 3 data and PDUFA, MK-3000 diabetic macular edema results, and sac-TMT ADC updates from Kelun Biotech, the analyst tells investors in a research note. New product cycles like Winrevair, Capvaxive, and Ohtuvayre also performed above expectations, while management continues to highlight M&A potential up to $15B, with capacity for larger deals, Goldman adds.